Literature DB >> 18622707

Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States.

Karen A Hennessey1, Andrea A Kim, Vivian Griffin, Nicoline T Collins, Cindy M Weinbaum, Keith Sabin.   

Abstract

Hepatitis B vaccination and targeted testing for hepatitis C virus (HCV) are recommended for jails with medical services available. This study estimates hepatitis B virus (HBV) and HCV infection prevalence among jail inmates, since most previous studies have been conducted among prison inmates. Prison and jail populations differ: jails hold a wide spectrum of persons for an average of 10-20 days, including persons awaiting arraignment, trial, conviction, or sentencing, while prisons typically hold convicted criminals for at least 1 year. A stratified random sample of sera obtained during routine syphilis testing of inmates entering jails in Chicago (March-April 2000), Detroit (March-August 1999), and San Francisco (June 1999-December 2000) was tested for serologic markers of HBV and HCV infection. All sera had been previously tested for antibody to HIV (anti-HIV). A total of 1,292 serum samples (12% of new inmates) was tested. Antibody to HCV (anti-HCV) prevalence was 13%. Antibody to hepatitis B core antigen (anti-HBc) prevalence was 19%, and hepatitis B surface antigen (HBsAg) prevalence was 0.9%; 12% had serologic evidence of hepatitis B vaccination. Hispanics had high rates of chronic HBV infection (3.6% HBsAg positive) along with Asians (4.7% HBsAg positive). Among HIV-infected persons, 38% were anti-HCV positive and 8.2% were HBsAg positive. Anti-HBc positivity was associated with anti-HCV positivity (aOR=4.58), anti-HIV positivity (aOR=2.94), syphilis infection (aOR=2.10), and previous incarceration (aOR=1.78). Anti-HCV-positivity was associated with anti-HBc positivity (aOR=4.44), anti-HIV-positivity (aOR=2.51), and previous incarceration (aOR=2.90). Jail entrants had high levels of HCV and HBV infection and HIV co-infection; HBV prevalence was comparable to previous prison studies, and HCV prevalence was lower than prison studies. Hispanics had an unexpectedly high rate of chronic hepatitis B infection and had the lowest rate of hepatitis B vaccination. The finding that hepatitis B vaccination coverage among jail entrants is lower than the general population, despite this population's increased risk for infection, highlights the need to support vaccination in jail settings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622707      PMCID: PMC2629523          DOI: 10.1007/s11524-008-9305-8

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  26 in total

1.  Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999.

Authors:  Juan D Ruiz; Fred Molitor; Julie A Plagenhoef
Journal:  AIDS       Date:  2002-11-08       Impact factor: 4.177

2.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

3.  The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997.

Authors:  Theodore M Hammett; Mary Patricia Harmon; William Rhodes
Journal:  Am J Public Health       Date:  2002-11       Impact factor: 9.308

4.  Hepatitis B vaccination practices in state and federal prisons.

Authors:  A Charuvastra; J Stein; B Schwartzapfel; A Spaulding; E Horowitz; G Macalino; J D Rich
Journal:  Public Health Rep       Date:  2001 May-Jun       Impact factor: 2.792

5.  Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention.

Authors:  Miriam J Alter; Wendi L Kuhnert; Lyn Finelli
Journal:  MMWR Recomm Rep       Date:  2003-02-07

6.  Hepatitis B vaccination of inmates in correctional facilities--Texas, 2000-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

7.  Seroepidemiology of hepatitis D (delta agent) and hepatitis B among Virginia State prisoners.

Authors:  R M Tucker; M J Gaffey; M J Fisch; D L Kaiser; R L Guerrant; D E Normansell
Journal:  Clin Ther       Date:  1987       Impact factor: 3.393

8.  Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention.

Authors:  Cindy Weinbaum; Rob Lyerla; Harold S Margolis
Journal:  MMWR Recomm Rep       Date:  2003-01-24

9.  Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities.

Authors:  Liza Solomon; Colin Flynn; Kelly Muck; John Vertefeuille
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

10.  Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system.

Authors:  J Baillargeon; H Wu; M J Kelley; J Grady; L Linthicum; K Dunn
Journal:  Public Health       Date:  2003-01       Impact factor: 2.427

View more
  32 in total

1.  Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary.

Authors:  Bálint Tresó; Erzsébet Barcsay; Anna Tarján; Gergely Horváth; Agnes Dencs; Andrea Hettmann; Mária Magdolna Csépai; Zoltán Gyori; Erzsébet Rusvai; Mária Takács
Journal:  J Urban Health       Date:  2012-02       Impact factor: 3.671

2.  Directly observed versus self-administered antiretroviral therapies: preference of HIV-positive jailed inmates in San Francisco.

Authors:  Parya Saberi; Nikolai H Caswell; Ross Jamison; Milton Estes; Jacqueline P Tulsky
Journal:  J Urban Health       Date:  2012-10       Impact factor: 3.671

3.  Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.

Authors:  Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

4.  Nursing case management, peer coaching, and hepatitis a and B vaccine completion among homeless men recently released on parole: randomized clinical trial.

Authors:  Adeline Nyamathi; Benissa E Salem; Sheldon Zhang; David Farabee; Betsy Hall; Farinaz Khalilifard; Barbara Leake
Journal:  Nurs Res       Date:  2015 May-Jun       Impact factor: 2.381

Review 5.  Opportunities to diagnose, treat, and prevent HIV in the criminal justice system.

Authors:  Curt G Beckwith; Nickolas D Zaller; Jeannia J Fu; Brian T Montague; Josiah D Rich
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

6.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

7.  Hepatitis C and B prevalence in Spanish prisons.

Authors:  P Saiz de la Hoya; A Marco; J García-Guerrero; A Rivera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-28       Impact factor: 3.267

8.  Hepatitis A/B vaccine completion among homeless adults with history of incarceration.

Authors:  Adeline M Nyamathi; Elizabeth Marlow; Catherine Branson; Mary Marfisee; Karabi Nandy
Journal:  J Forensic Nurs       Date:  2012-01-06       Impact factor: 1.175

Review 9.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

10.  Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System.

Authors:  Matthew J Akiyama; Fatos Kaba; Zachary Rosner; Howard Alper; Aimee Kopolow; Alain H Litwin; Homer Venters; Ross MacDonald
Journal:  Public Health Rep       Date:  2016-12-14       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.